Posted by Michael Wonder on 28 Nov 2019
Pfizer's Ibrance scores second-line breast cancer approval via NICE’s Cancer Drugs Fund
28 November 2019 - Around 3,200 women in England could be eligible for treatment.
Pfizer’s Ibrance has been approved by the National Institute for Health and Care Excellence in England through its Cancer Drugs Fund as a second-line treatment for advanced breast cancer.
Ibrance (palbociclib), in combination with fluvestrant has been approved for use via the Cancer Drugs Fund in women with previously treated, HR positive and HER2 negative metastatic breast cancer.
